No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Boan Biotech’s Denosumab Biosimilar Approved in China
On 27 May 2024, Boan Biotech announced that its Boluojia® (BA11021, denosumab injection, 120mg) received marketing approval from China’s National Medical Products Administration (NMPA) as biosimilar to Amgen’s Xgeva®. Boluojia® is indicated for the treatment of giant...